Legend Biotech (LEGN) Interim CEO Alan Bash Receives Award

What Happened

• Alan Bash, Interim CEO of Legend Biotech (LEGN), received a grant of 4,908 restricted share units (RSUs) on August 14, 2026. The award was reported at $0.00 per share (aggregate $0), i.e., a compensation grant rather than an open-market purchase or sale.
• Each RSU is a contingent right to receive one ordinary share of the company upon settlement (see footnote F2). This type of award is typically part of executive compensation and not an immediate market signal like a purchase or sale.

Key Details

• Transaction date: 2026-08-14; Form 4 filed: 2026-08-18 (4 days after the transaction). Form 4s are generally due within two business days, so this filing appears later than the usual deadline.
• Transaction type/code: Award/Grant (A).
• Amount: 4,908 RSUs @ $0.00 (aggregate $0).
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes:
  • F1: Ordinary shares may be represented by ADSs; 1 ADS = 2 ordinary shares.
  • F2: The RSUs vest 1/3 on each of July 27, 2027, July 27, 2028, and July 27, 2029, subject to continued service.

Context

• RSUs are a form of compensation: they represent a promise to deliver ordinary shares in the future if vesting conditions (here, continued service) are met. They are different from an outright purchase (which can be interpreted as a direct bullish signal) or a sale.
• For retail investors, such grants are common for executives and should be viewed as part of compensation structure rather than a direct indicator of insider buy/sell sentiment.